CN114341158B - 包含成纤维细胞活化蛋白配体的化合物及其用途 - Google Patents

包含成纤维细胞活化蛋白配体的化合物及其用途 Download PDF

Info

Publication number
CN114341158B
CN114341158B CN202080062641.3A CN202080062641A CN114341158B CN 114341158 B CN114341158 B CN 114341158B CN 202080062641 A CN202080062641 A CN 202080062641A CN 114341158 B CN114341158 B CN 114341158B
Authority
CN
China
Prior art keywords
amino acid
group
compound
compound according
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080062641.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN114341158A (zh
Inventor
F·奥斯特坎普
D·兹博拉尔斯基
E·施奈德
C·哈泽
M·帕施克
A·赫内
J·翁格维斯
C·斯梅林
U·赖内克
A·布雷登贝克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3B Pharmaceuticals GmbH
Original Assignee
3B Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP19000325.1A external-priority patent/EP3763726A1/en
Application filed by 3B Pharmaceuticals GmbH filed Critical 3B Pharmaceuticals GmbH
Priority to CN202411047668.1A priority Critical patent/CN118955620A/zh
Priority to CN202411047674.7A priority patent/CN118930608A/zh
Publication of CN114341158A publication Critical patent/CN114341158A/zh
Application granted granted Critical
Publication of CN114341158B publication Critical patent/CN114341158B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202080062641.3A 2019-07-08 2020-07-08 包含成纤维细胞活化蛋白配体的化合物及其用途 Active CN114341158B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202411047668.1A CN118955620A (zh) 2019-07-08 2020-07-08 包含成纤维细胞活化蛋白配体的化合物及其用途
CN202411047674.7A CN118930608A (zh) 2019-07-08 2020-07-08 包含成纤维细胞活化蛋白配体的化合物及其用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19000325.1 2019-07-08
EP19000325.1A EP3763726A1 (en) 2019-07-08 2019-07-08 Compounds comprising a fibroblast activation protein ligand and use thereof
EP19198810.4 2019-09-20
EP19198810 2019-09-20
PCT/EP2020/069308 WO2021005131A1 (en) 2019-07-08 2020-07-08 Compounds comprising a fibroblast activation protein ligand and use thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202411047674.7A Division CN118930608A (zh) 2019-07-08 2020-07-08 包含成纤维细胞活化蛋白配体的化合物及其用途
CN202411047668.1A Division CN118955620A (zh) 2019-07-08 2020-07-08 包含成纤维细胞活化蛋白配体的化合物及其用途

Publications (2)

Publication Number Publication Date
CN114341158A CN114341158A (zh) 2022-04-12
CN114341158B true CN114341158B (zh) 2024-08-06

Family

ID=71409440

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202080062641.3A Active CN114341158B (zh) 2019-07-08 2020-07-08 包含成纤维细胞活化蛋白配体的化合物及其用途
CN202411047668.1A Pending CN118955620A (zh) 2019-07-08 2020-07-08 包含成纤维细胞活化蛋白配体的化合物及其用途
CN202411047674.7A Pending CN118930608A (zh) 2019-07-08 2020-07-08 包含成纤维细胞活化蛋白配体的化合物及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202411047668.1A Pending CN118955620A (zh) 2019-07-08 2020-07-08 包含成纤维细胞活化蛋白配体的化合物及其用途
CN202411047674.7A Pending CN118930608A (zh) 2019-07-08 2020-07-08 包含成纤维细胞活化蛋白配体的化合物及其用途

Country Status (12)

Country Link
US (1) US20220315554A1 (https=)
EP (1) EP3997104A1 (https=)
JP (2) JP7801207B2 (https=)
KR (1) KR20220032078A (https=)
CN (3) CN114341158B (https=)
AU (1) AU2020309161A1 (https=)
BR (1) BR112022000144A2 (https=)
CA (1) CA3145872A1 (https=)
CL (1) CL2022000016A1 (https=)
IL (2) IL289673B2 (https=)
MX (1) MX2022000251A (https=)
WO (1) WO2021005131A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3997103T3 (fi) 2019-07-08 2025-02-03 3B Pharmaceuticals Gmbh Fibroblastien aktivaatioproteiinin ligandia käsittäviä yhdisteitä ja niiden käyttö
CN115943312A (zh) 2020-05-07 2023-04-07 法国居里学院 免疫抑制性成纤维细胞群体的生物标志物antxr1及其在预测对免疫疗法的反应中的用途
WO2022115778A1 (en) * 2020-11-30 2022-06-02 Rayzebio, Inc. Radiopharmaceutical conjugate compositions and uses thereof
EP4050018A1 (en) * 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
TW202340226A (zh) * 2021-12-17 2023-10-16 德商３Ｂ製藥有限公司 碳酸酐酶ix配位體
EP4475900A1 (en) 2022-02-09 2024-12-18 Novartis AG Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent
IL322552A (en) * 2023-02-10 2025-10-01 Chengdu New Radiomedicine Tech Co Ltd Polypeptide compound and its use
AU2024221970A1 (en) 2023-02-14 2025-09-11 Radiovaxx Gmbh Drug and treatment method
WO2024198838A1 (zh) * 2023-03-27 2024-10-03 晶核生物医药科技(南京)有限公司 环状多肽类化合物及其应用
EP4692105A1 (en) * 2023-03-27 2026-02-11 Bivision Pharmaceuticals, Inc Cyclic polypeptide compound and use thereof
WO2024198836A1 (zh) * 2023-03-27 2024-10-03 晶核生物医药科技(南京)有限公司 环状多肽类化合物及其应用
CN118930606A (zh) * 2023-05-11 2024-11-12 成都纽瑞特医疗科技股份有限公司 靶向成纤维细胞活化蛋白的多肽放射性核素配合物及其应用
WO2025011611A1 (zh) * 2023-07-11 2025-01-16 江苏恒瑞医药股份有限公司 一种成纤维细胞活化蛋白配体及其用途
WO2025046043A1 (en) 2023-08-31 2025-03-06 Stichting Radboud Universitair Medisch Centrum Endometriosis tracer
WO2025082283A1 (zh) * 2023-10-16 2025-04-24 四川科伦博泰生物医药股份有限公司 环肽结构的配体化合物及其核素标记物、药物组合物及应用
US20250186630A1 (en) 2023-12-12 2025-06-12 Viewpoint Molecular Targeting, Inc. Fibroblast activation protein targeting peptides
WO2025163556A1 (en) 2024-02-01 2025-08-07 Novartis Ag Methods for treating cancer
WO2026008525A1 (en) * 2024-07-01 2026-01-08 Bayer Aktiengesellschaft Stable radionuclide-containing formulations
WO2026017046A1 (zh) * 2024-07-19 2026-01-22 晶核生物医药科技(南京)有限公司 一种环多肽、其制备方法和应用
WO2026021314A1 (zh) * 2024-07-22 2026-01-29 山东威智知科药业有限公司 Fap化合物及其用途
WO2026041109A1 (zh) * 2024-08-23 2026-02-26 苏州博锐创合医药有限公司 成纤维细胞活化蛋白抑制剂及其用途
CN120590466A (zh) * 2025-08-06 2025-09-05 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) 一种靶向成纤维细胞活化蛋白的化合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302306A (zh) * 2012-03-21 2015-01-21 巴克斯特国际公司 Tfpi抑制剂及其使用方法
CN106046121A (zh) * 2016-06-20 2016-10-26 郑州大学 一种靶向fap的抗血管生成肽z‑gp‑v1及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
ATE357509T1 (de) 1997-09-29 2007-04-15 Point Therapeutics Inc Stimulierung von hämatopoietischen zellen im vitro
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
EP1268550A2 (en) 2000-03-17 2003-01-02 Boehringer Ingelheim Pharma KG Human fap-alpha-specific antibodies
EP1452868A2 (en) * 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
US7374898B2 (en) * 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
US7399869B2 (en) 2005-05-19 2008-07-15 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
WO2008116054A1 (en) 2007-03-20 2008-09-25 Trustees Of Tufts College Inhibitors of fibroblast activation protein, and methods of use thereof
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
WO2010036814A1 (en) 2008-09-25 2010-04-01 Molecular Insight Pharmaceuticals, Inc. Selective seprase inhibitors
CA2776037A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd Anti-fibroblast activation protein antibodies and methods and uses thereof
CA2806021C (en) 2010-08-13 2019-05-21 Roche Glycart Ag Anti-fap antibodies and methods of use
WO2013107820A1 (en) 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
RU2743781C2 (ru) * 2014-06-10 2021-02-25 3Б Фармасьютикалз Гмбх Конъюгат, содержащий лиганд рецепторов нейротензина, и его применение
WO2016146174A1 (en) * 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
WO2017127007A1 (en) * 2016-01-20 2017-07-27 Poypeptide Laboratories Holding (Ppl) Ab METHOD FOR PREPARATION OF PEPTIDES WITH psWANG LINKER
CN109689115A (zh) 2016-06-10 2019-04-26 拜耳制药股份公司 放射性药物配合物
CN105949282B (zh) * 2016-06-20 2020-06-16 郑州大学 一种靶向fap的抗血管生成肽z-gp-v2及其应用
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
EA202090776A1 (ru) 2017-10-23 2020-07-27 Дзе Джонс Хопкинс Юниверсити Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)
FI3997103T3 (fi) * 2019-07-08 2025-02-03 3B Pharmaceuticals Gmbh Fibroblastien aktivaatioproteiinin ligandia käsittäviä yhdisteitä ja niiden käyttö

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302306A (zh) * 2012-03-21 2015-01-21 巴克斯特国际公司 Tfpi抑制剂及其使用方法
CN106046121A (zh) * 2016-06-20 2016-10-26 郑州大学 一种靶向fap的抗血管生成肽z‑gp‑v1及其应用

Also Published As

Publication number Publication date
CN118955620A (zh) 2024-11-15
EP3997104A1 (en) 2022-05-18
IL289673A (en) 2022-03-01
MX2022000251A (es) 2022-02-21
IL324399A (en) 2026-01-01
CA3145872A1 (en) 2021-01-14
KR20220032078A (ko) 2022-03-15
CL2022000016A1 (es) 2022-08-19
CN114341158A (zh) 2022-04-12
IL289673B1 (en) 2025-12-01
US20220315554A1 (en) 2022-10-06
IL289673B2 (en) 2026-04-01
AU2020309161A1 (en) 2022-01-27
JP2026062901A (ja) 2026-04-10
JP7801207B2 (ja) 2026-01-16
BR112022000144A2 (pt) 2022-02-22
WO2021005131A1 (en) 2021-01-14
CN118930608A (zh) 2024-11-12
JP2022541752A (ja) 2022-09-27

Similar Documents

Publication Publication Date Title
CN114341158B (zh) 包含成纤维细胞活化蛋白配体的化合物及其用途
CN114341159B (zh) 包含成纤维细胞活化蛋白配体的化合物及其用途
US20230212549A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
US20240115745A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
AU2022410422B2 (en) Carbonic anhydrase ix ligands
EP3763726A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
TW202334177A (zh) 包含纖維母細胞活化蛋白配體之化合物和彼之用途
AU2023337515A1 (en) Prostate specific membrane antigen (psma) ligands and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant